GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (FRA:KH6) » Definitions » Beneish M-Score

NewAmsterdam Pharma Co NV (FRA:KH6) Beneish M-Score : -1.46 (As of May. 15, 2024)


View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.46 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for NewAmsterdam Pharma Co NV's Beneish M-Score or its related term are showing as below:

FRA:KH6' s Beneish M-Score Range Over the Past 10 Years
Min: -1.46   Med: -1.46   Max: -1.46
Current: -1.46

During the past 4 years, the highest Beneish M-Score of NewAmsterdam Pharma Co NV was -1.46. The lowest was -1.46. And the median was -1.46.


NewAmsterdam Pharma Co NV Beneish M-Score Historical Data

The historical data trend for NewAmsterdam Pharma Co NV's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NewAmsterdam Pharma Co NV Beneish M-Score Chart

NewAmsterdam Pharma Co NV Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Beneish M-Score
- - - -1.46

NewAmsterdam Pharma Co NV Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Beneish M-Score Get a 7-Day Free Trial - - - - -1.46

Competitive Comparison of NewAmsterdam Pharma Co NV's Beneish M-Score

For the Biotechnology subindustry, NewAmsterdam Pharma Co NV's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NewAmsterdam Pharma Co NV's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NewAmsterdam Pharma Co NV's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where NewAmsterdam Pharma Co NV's Beneish M-Score falls into.



NewAmsterdam Pharma Co NV Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of NewAmsterdam Pharma Co NV for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 6.6235+0.528 * 1+0.404 * 0.7756+0.892 * 0.1333+0.115 * 0.1603
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 15.4819+4.679 * -0.087851-0.327 * 1.9045
=-1.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was €1.73 Mil.
Revenue was €12.92 Mil.
Gross Profit was €12.92 Mil.
Total Current Assets was €318.01 Mil.
Total Assets was €318.29 Mil.
Property, Plant and Equipment(Net PPE) was €0.09 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.05 Mil.
Selling, General, & Admin. Expense(SGA) was €27.30 Mil.
Total Current Liabilities was €45.76 Mil.
Long-Term Debt & Capital Lease Obligation was €0.00 Mil.
Net Income was €-162.25 Mil.
Gross Profit was €-4.79 Mil.
Cash Flow from Operations was €-129.50 Mil.
Total Receivables was €1.95 Mil.
Revenue was €96.94 Mil.
Gross Profit was €96.94 Mil.
Total Current Assets was €451.21 Mil.
Total Assets was €451.70 Mil.
Property, Plant and Equipment(Net PPE) was €0.15 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.01 Mil.
Selling, General, & Admin. Expense(SGA) was €13.23 Mil.
Total Current Liabilities was €34.04 Mil.
Long-Term Debt & Capital Lease Obligation was €0.06 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1.725 / 12.921) / (1.954 / 96.943)
=0.133504 / 0.020156
=6.6235

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(96.943 / 96.943) / (12.921 / 12.921)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (318.007 + 0.093) / 318.288) / (1 - (451.212 + 0.145) / 451.701)
=0.000591 / 0.000762
=0.7756

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=12.921 / 96.943
=0.1333

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.008 / (0.008 + 0.145)) / (0.045 / (0.045 + 0.093))
=0.052288 / 0.326087
=0.1603

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(27.3 / 12.921) / (13.23 / 96.943)
=2.11284 / 0.136472
=15.4819

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 45.756) / 318.288) / ((0.057 + 34.038) / 451.701)
=0.143757 / 0.075481
=1.9045

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-162.251 - -4.792 - -129.497) / 318.288
=-0.087851

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

NewAmsterdam Pharma Co NV has a M-score of -1.46 signals that the company is likely to be a manipulator.


NewAmsterdam Pharma Co NV Beneish M-Score Related Terms

Thank you for viewing the detailed overview of NewAmsterdam Pharma Co NV's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


NewAmsterdam Pharma Co NV (FRA:KH6) Business Description

Traded in Other Exchanges
Address
Gooimeer 2-35, Naarden, NH, NLD, 1411 DC
NewAmsterdam Pharma Co NV is a clinical-stage company focused on the research and development of transformative therapies for metabolic diseases and Alzheimer's disease.

NewAmsterdam Pharma Co NV (FRA:KH6) Headlines

No Headlines